A Novel Two-Stage, Transdisciplinary Study Identifies Digoxin as a Possible Drug for Prostate Cancer Treatment
Open Access
- 1 June 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 1 (1) , 68-77
Abstract
Identification of novel indications for commonly prescribed drugs could accelerate translation of therapies. We investigated whether any clinically used drugs might be useful in treating prostate cancer by coupling an efficient, high-throughput laboratory-based screen and a large prospective cohort study. In stage one, we conducted an in vitro prostate cancer cell cytotoxicity screen of 3,187 compounds. Digoxin emerged as the leading candidate, given its potency in inhibiting proliferation in vitro (the concentration of the drug at which proliferation was inhibited by 50%: mean of 163 nM) and its common use. In stage two, we evaluated the association between the leading candidate drug from stage one and prostate cancer risk in 47,884 men followed up from 1986 through 2006. Regular digoxin users [vs nonusers: relative risk (RR) = 0.76; 95% confidence interval (CI), 0.61–0.95], especially users for ≥10 years (RR = 0.54; 95% CI, 0.37–0.79; P trend < 0.001), had a lower prostate cancer risk. Digoxin was highly potent in inhibiting prostate cancer cell growth in vitro, and its use was associated with a 25% lower prostate cancer risk. Significance: Our two-stage transdisciplinary approach for drug repositioning provides compelling justification for further mechanistic and possibly clinical testing of the leading nonchemotherapy candidate, digoxin, a cardiac glycoside, as a drug for prostate cancer treatment. Perhaps of equal importance, our study illustrates the power of the transdisciplinary approach in translational cancer research. By coupling laboratory and epidemiologic methods and thinking, we reduced the probability of identifying false-positive candidate drugs for the next steps in testing. Cancer Discovery; 1(1); 68–77. ©2011 AACR. Read the Commentary on this article by Spitz et al., p. 21 This article is highlighted in the In This Issue feature, p. 4Keywords
This publication has 23 references indexed in Scilit:
- Cardiac Glycosides Inhibit p53 Synthesis by a Mechanism Relieved by Src or MAPK InhibitionCancer Research, 2009
- Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growthProceedings of the National Academy of Sciences, 2008
- Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control studyBreast Cancer Research, 2008
- DNA Hypomethylation Arises Later in Prostate Cancer Progression than CpG Island Hypermethylation and Contributes to Metastatic Tumor HeterogeneityCancer Research, 2008
- Risk factors for prostate cancer incidence and progression in the health professionals follow‐up studyInternational Journal of Cancer, 2007
- Diet After Diagnosis and the Risk of Prostate Cancer Progression, Recurrence, and Death (United States)Cancer Causes & Control, 2006
- The Pharmaceutical Industry — Prices and ProgressNew England Journal of Medicine, 2004
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Ouabain sensitivity is linked to ras-transformation in human HOS cellsBiochemical and Biophysical Research Communications, 1986